Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shmuel Yaccoby

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Stem Cells (Dayton, Ohio)|July 7, 2011
Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in boneXin Li, Wen Ling, Angela Pennisi, et al.
Blood|May 27, 2006
The molecular classification of multiple myelomaFenghuang Zhan, Yongsheng Huang, Simona Colla, et al.
Blood|April 23, 2013
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myelomaSaad Z Usmani, Jeffrey Sawyer, Adam Rosenthal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 14, 2007
Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implicationsRonald Walker, Bart Barlogie, Jeffrey Haessler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2016
Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan TransplantsYogesh S Jethava, Alan Mitchell, Joshua Epstein, et al.
Current Research in Translational Medicine|April 24, 2021
PHF19 inhibition as a therapeutic target in multiple myelomaCarolina D Schinke, Jordan T Bird, Pingping Qu, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 22, 2014
Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patientsSusann Szmania, Natalia Lapteva, Tarun Garg, et al.
Blood|April 23, 2017
Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myelomaLeo Rasche, Edgardo Angtuaco, James E McDonald, et al.
Genome Research|December 22, 2021
Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancersAneta Mikulasova, Daniel Kent, Marco Trevisan-Herraz, et al.
Molecular Cancer Therapeutics|September 3, 2009
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myelomaFrits van Rhee, Susann M Szmania, Myles Dillon, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Stem Cells (Dayton, Ohio)|July 7, 2011
Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in boneXin Li, Wen Ling, Angela Pennisi, et al.
Blood|May 27, 2006
The molecular classification of multiple myelomaFenghuang Zhan, Yongsheng Huang, Simona Colla, et al.
Blood|April 23, 2013
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myelomaSaad Z Usmani, Jeffrey Sawyer, Adam Rosenthal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 14, 2007
Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implicationsRonald Walker, Bart Barlogie, Jeffrey Haessler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2016
Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan TransplantsYogesh S Jethava, Alan Mitchell, Joshua Epstein, et al.
Current Research in Translational Medicine|April 24, 2021
PHF19 inhibition as a therapeutic target in multiple myelomaCarolina D Schinke, Jordan T Bird, Pingping Qu, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 22, 2014
Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patientsSusann Szmania, Natalia Lapteva, Tarun Garg, et al.
Blood|April 23, 2017
Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myelomaLeo Rasche, Edgardo Angtuaco, James E McDonald, et al.
Genome Research|December 22, 2021
Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancersAneta Mikulasova, Daniel Kent, Marco Trevisan-Herraz, et al.
Molecular Cancer Therapeutics|September 3, 2009
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myelomaFrits van Rhee, Susann M Szmania, Myles Dillon, et al.
Pageof 7